The evolution from time-consuming manual reviews to automated detection and now to intelligent action is reimagining the ...

Physicians stand to earn big money when signing up patients for drug trials. And lately, some of those trials have been ...

The local pharmacy used to be the default place to fill prescriptions, but like just about everything else, technology is ...

Vaxcyte aims to revolutionize the pneumococcal vaccine market with VAX-31. Click here to read an analysis of PCVX stock now.

China’s focus on first or best-in-class oncology drugs and innovative R&D will help it to secure further licensing deals in ...

Becton Dickinson and Co, iShares U.S. Pharmaceuticals ETF, BlackRock Health Sciences Trust. Read 's Market Analysis on Investing.com ...

A notable finding is that audiences are split on whether they see more pharma ads in 2025 compared to 2024. Nearly half of ...

In today’s Pharmaceutical Executive Daily, Eli Lilly reports positive topline Phase III results for retatrutide, the FDA ...

Entasis’ Nuzolvence and GSK’s Blujepa are the first antibiotic approvals in gonorrhoea in over 30 years in the US.

If the FDA ceases to be a predictable source of regulatory guidance, then China will gain a significant advantage in the race ...

We found that one-third of pharmaceutical companies proactively released the launch price of their medications between 2022 and 2024, and another third released them reactively. Smaller public ...

Shares in argenx fell after the pharmaceutical company said it would stop late-stage trials for an experimental drug to treat thyroid eye disease due to lack of efficacy. In European afternoon trading ...